Get the Stockscreener App
2.94
6.67%
-0.21
After Hours:
2.95
0.01
+0.34%
Recursion Pharmaceuticals Inc stock is traded at $2.94, with a volume of 19.07M.
It is down -6.67% in the last 24 hours and down -19.89% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
See More
Previous Close:
$3.15
Open:
$3.09
24h Volume:
19.07M
Relative Volume:
1.01
Market Cap:
$1.55B
Revenue:
$74.68M
Net Income/Loss:
$-644.76M
P/E Ratio:
-1.9826
EPS:
-1.4829
Net Cash Flow:
$-380.44M
1W Performance:
-9.54%
1M Performance:
-19.89%
6M Performance:
-37.71%
1Y Performance:
-50.75%
1-Day Range:
$2.91
$3.12
1-Week Range:
$2.91
$3.33
52-Week Range:
$2.91
$7.18
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
2.94 | 1.66B | 74.68M | -644.76M | -380.44M | -1.4829 |
VRTX
Vertex Pharmaceuticals Inc
|
433.07 | 115.27B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
737.71 | 80.00B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
691.40 | 43.00B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
317.36 | 43.52B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
283.03 | 30.74B | 5.36B | 287.73M | 924.18M | 2.5229 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
Recursion Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
Recursion Pharmaceuticals (RXRX) down 16.5% since last earnings report: Can it rebound? - MSN
RXRX Faces Stock Strain as Bank of America Slashes Price Target - StocksToTrade
Recursion Pharmaceuticals (NASDAQ:RXRX) Reaches New 52-Week LowWhat's Next? - MarketBeat
Recursion Pharmaceuticals stock hits 52-week low at $2.98 By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals (RXRX) Has Fallen 16.5% Since Previous Earnings Report: Is a Recovery Possible? - Bitget
Recursion Pharmaceuticals (RXRX) Down 16.5% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
RXRX Stock: Why Did Nvidia Offload AI Drug Developer Recursion? - cmcmarkets.com
New Recursion CMO Puts Oncology Experience At Center Of Investor Focus - Sahm
Recursion names Vicki Goodman as CMO - MSN
Recursion Pharmaceuticals Appoints Vicki Goodman, M.D. as Chief Medical Officer to Advance Clinical Pipeline and AI-Driven Drug Development 1 - Minichart
Recursion Pharmaceuticals | 8-K: Current report - Moomoo
Recursion Pharmaceuticals Names New Chief Medical Officer - TipRanks
Recursion appoints Vicki Goodman as Chief Medical Officer; David Mauro to transition to advisor - TradingView
Vicki Goodman to become Recursion (NASDAQ: RXRX) chief medical officer - Stock Titan
[Form 4] RECURSION PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
EXEL: Former Executive Joins Recursion Pharmaceuticals as New CM - GuruFocus
Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer - marketscreener.com
Recursion taps former FDA reviewer Vicki Goodman as chief medical officer - Stock Titan
Assessing Recursion Pharmaceuticals (RXRX) Valuation After Prolonged Share Price Weakness - Sahm
Recursion Pharmaceuticals Stock (RXRX) Opinions on Roche's AI Drug Development Commitment - quiverquant.com
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Prediction: The "Trough of Disillusionment" Will Create the Best Buying Opportunity for Artificial Intelligence (AI) Stocks in 2026 - The Motley Fool
Recursion Pharmaceuticals Details AI-Driven Drug Pipeline, Sanofi/Roche Milestones, Runway to 2028 - MarketBeat
Recursion’s Khan: AI will be judged by the medicines it makes - BioCentury
Recursion Pharmaceuticals (RXRX) Advances While Market Declines: Some Information for Investors - Yahoo Finance
What makes Recursion Pharmaceuticals (RXRX) so attractive - MSN
Ben Taylor Sells 7,956 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock - MarketBeat
Recursion Pharma CFO Taylor sells $26970 in shares - Investing.com
CFO of Recursion Pharmaceuticals (RXRX) sells 7,956 shares under 10b5-1 plan - Stock Titan
Recursion Pharmaceuticals sets post-hype agenda at LeerinkPartners healthcare event - Traders Union
BofA lowers PT on Recursion Pharmaceuticals (RXRX), keeps a hold rating - MSN
Jim Cramer on Recursion Pharmaceuticals: “It’s a let down, big let down” - MSN
Why Recursion Pharmaceuticals, Inc. (RXRX)'s upside case hasn't fully convinced yet - MSN
RXRX SEC FilingsRecursion Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Is Recursion Pharmaceuticals, Inc. (RXRX) the best fundamentally strong penny stock to buy? - MSN
Costco, AMD, Recursion Pharmaceuticals, Cipher Mining And Snowflake: Why These 5 Stocks Are On Investors' Radars Today - AOL.com
Measuring the AI Bubble - Pharmaceutical Executive
Jim Cramer on Recursion Pharmaceuticals: “It’s a Let Down, Big Let Down” - Insider Monkey
A Look At Recursion Pharmaceuticals (RXRX) Valuation After Q4 Beat And AI Clinical Progress - Sahm
PARG inhibitors disclosed in Recursion Pharmaceuticals patent - BioWorld MedTech
Recursion Pharmaceuticals and Applied Digital shares fall after Nvidia exits stakes - MSN
Needham Retains Buy Rating on Recursion Pharmaceuticals, Maintains PT at $8 - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) CEO Sells $94,798.30 in Stock - MarketBeat
Recursion (NASDAQ: RXRX) director converts 20K Class B, gifts 20K A - Stock Titan
Jim Cramer on Recursion: “It is so low that it comes in under the category of speculative” - MSN
Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Recent 1‑Year Share Slump Accurately - Yahoo Finance
How Recursion’s AI Proof of Concept and Equity Raise Will Impact Recursion Pharmaceuticals (RXRX) Investors - Yahoo Finance
A Look At Recursion Pharmaceuticals (RXRX) Valuation After AI Milestone And Improved Quarterly Results - Yahoo Finance
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.03%
2.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):